[1]
S. Weidinger, ‚ÄúTralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis‚ÄĚ, J of Skin, vol. 4, no. 6, p. s100, Oct. 2020.